Commentary

Video

Dr Jain on the Importance of Novel Therapies in Pediatric Patients With Bleeding Disorders

Akshat Jain, MBBS, discusses the importance of novel therapies in the treatment of pediatric patients with beleeding disorders.

Akshat Jain, MBBS, director, Inherited Bleeding Disorder and Thrombosis program, director, Sickle Cell Disease Program for Children and Young Adults, member, the clinical pediatric hematology/oncology, faculty, Stem Cell Transplantation, the Department of Pediatrics and Clinical Medicine, assistant professor, pediatrics, Hematology/Oncology Division, assistant professor, School of Public Health, Loma Linda University School of Medicine and Children’s Hospital, discusses the importance of novel therapies in the treatment of pediatric patients with beleeding disorders.

Related Videos
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD